
    
      This is a multi-center, open-label, Phase 2 study designed to evaluate the safety,
      tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active
      biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination
      with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).
    
  